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ABSTRACT
Background: It is unknown whether habitual intake of dietary fla-
vonoids, known for their antioxidative and anti-inflammatory prop-
erties, affects longitudinal change in lung function.
Objective: We investigated whether different flavonoid subclasses
present in the habitual diet were associated with beneficial changes
in lung function over time in the elderly.
Design: This longitudinal analysis included 839 participants from the
VA (Veterans Affairs) Normative Aging Study whose lung function
[forced expiratory volume in 1 s (FEV1) and forced vital capacity
(FVC)] was measured at 2 and up to 5 visits between 1992 and 2008
(n = 2623 measurements). Yearly average intake of major flavonoid
subclasses (anthocyanins, flavanones, flavan-3-ols, flavonols, fla-
vones, and polymers) was calculated from food-frequency question-
naires at each visit. We estimated adjusted differences in annual
change in lung function associated with each flavonoid subclass,
categorized into quartiles, in linear mixed-effects regression models
after adjustment for lifestyle and dietary confounders.
Results: Strong inverse associations were found between anthocyanin
intake and age-related decline in lung function. Independent of dietary and
nondietary risk factors, slower rates of FEV1 and FVC decline by 23.6
(95% CI: 16.6, 30.7) and 37.3 (95% CI: 27.8, 46.8) mL/y, respectively,
were observed in participants in the fourth quartile of intake compared
with participants in the first quartile (P-trend , 0.0001). The protective
associations observed for anthocyanin intake were present in both current/
former and never smokers. Compared with no or very low intakes, an
intake of $2 servings of anthocyanin-rich blueberries/wk was associated
with slower decline in FEV1 and FVC by 22.5 (95% CI: 10.8, 34.2) and
37.9 (95% CI: 22.1, 53.7) mL/y, respectively. To a lesser extent, higher
flavan-3-ol intake was also associated with slower lung function decline.
Conclusions: An attenuation of age-related lung function decline
was associated with higher dietary anthocyanin intake in this lon-
gitudinal sample of predominantly elderly men. Further prospective
studies are needed to confirm these novel associations. Am J
Clin Nutr 2016;103:542–50.
Keywords: anthocyanins, clinical epidemiology, diet, flavonoids,
lung function tests
INTRODUCTION
Lung function starts to decline in the third decade of life (1), but
with different rates of decline across individuals (2). Lower lung
function is a strong predictor of mortality (3, 4), and faster lung
function decline has been associated with increased risks of
hospitalizations related to chronic obstructive pulmonary disease
(5), a leading cause of mortality in all countries (6). There are
multiple sources of the heterogeneity in lung function decline in
adults, and the available evidence from population-based studies
suggests that a diet rich in antioxidants is positively related to lung
function and slower age-related decline in lung function (7). For
vitamin C, b-carotene, and fiber, prospective and cross-sectional
studies show that individuals with high intakes had better lung
function than those with low intakes (8–13), whereas less con-
sistent findings are observed for other antioxidants, including
vitamin E (10, 11, 14, 15).
Growing evidence supports the hypothesis that dietary fla-
vonoids may also have a beneficial effect on lung function.
Experimental studies in animals have found specific flavonoids
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Supplemental Material can be found at:
to attenuate airway hyperresponsiveness, inflammation, and
remodeling (16–19). Cross-sectional findings from 2 population-
based studies in adults also observed positive associations between
dietary flavan-3-ol and flavonol intake with forced expiratory
volume in 1 s (FEV1)
10 and with forced vital capacity (FVC),
respectively (20, 21). To our knowledge, no longitudinal studies to
date have evaluated if specific flavonoid subclasses are associated
with slower rates of age-related lung function decline.
In addition, no studies to our knowledge have examined the
impact of dietary anthocyanin intake on lung function. An-
thocyanins are a subclass of flavonoids derived from fruit,
predominantly berries, which have been shown to be asso-
ciated with lower risk of hypertension and myocardial in-
farction (22, 23) and with lower levels of inflammation (24).
Findings from acute and short-term clinical trials also suggest
beneficial effects of both purified anthocyanins and intake of
berries on a range of inflammatory biomarkers (25–27). The
ingestion of anthocyanin-rich strawberries and fruit juice has
also been shown to improve antioxidant enzyme activities
and plasma antioxidant capacity in experimental human
studies, providing evidence of beneficial effects on oxidative
stress, another key mechanism involved in lung function (28,
29).
Given the previous findings observed for flavonoid intake with
lung function (20, 21), and for flavonoid intakewith inflammation
and oxidative stress biomarkers (24, 28, 29), we hypothesized
that a higher habitual intake of anthocyanins, flavonols, flavan-3-
ols, and their polymeric forms would be associated with bene-
ficial changes in lung function. We investigated if dietary intake
of the major flavonoid subclasses was associated with a slower
age-related decline in lung function in a community-based cohort
of elderly men living in the Boston area.
METHODS
Study participants included in this longitudinal analysis were
enrolled in the VA (Veterans Affairs) Normative Aging Study, an
ongoing longitudinal study of aging established in 1963, details
of which have been published previously (30). Briefly, the
Normative Aging Study is a closed cohort of 2280 male vol-
unteers from the Greater Boston area aged 21–80 y at entry, who
enrolled after an initial health screening determined that they
were free of known chronic medical conditions. Participants
have undergone detailed examinations every 3–5 y, including
routine physical examinations, laboratory tests, collection of
medical history information, and completion of questionnaires
on smoking history, food intake, and other factors that may in-
fluence health, which were confirmed by a trained interviewer.
Physical examinations included measurement of height and lung
function (FEV1 and FVC). Pulmonary disorders confirmed by
a physician (asthma, chronic bronchitis, or emphysema) and
smoking history were collected through the American Thoracic
Society questionnaire (31). The present study was approved by
the human research committees of the Harvard School of Public
Health and the Veterans Affairs Boston Health care System, and
written informed consent was obtained from subjects before
participation.
For the present analysis, there were 1281 eligible participants
with at least 1 visit between May 1992 and October 2008, when
computations of dietary flavonoid intake were available for all
self-administered semi-quantitative food-frequency question-
naires (FFQs). Of those eligible, there were 1048 participants
with at least 1 visit with data available on spirometry, dietary
flavonoid intake, and covariates of interest (Supplemental
Figure 1). This analysis included 839 participants whose lung
function was measured and who completed an FFQ in at least 2
visits (n = 2623 visits); there were 287 participants with 2 visits,
262 with 3 visits, 187 with 4 visits, and 103 with 5 visits. Visits
with implausible values for total energy intake for men (,800 or
.4200 kcal) were excluded from the analysis. For additional
description of the study participation, please refer to the
Methods section of the Supplemental Material.
Outcome assessment
Pulmonary function tests were performed as previously reported
(32), and acceptability of spirograms was judged according to
American Thoracic Society standards. Briefly, a water-filled re-
cording spirometer was used to obtain measures of FEV1 (mL)
and FVC (mL), with values adjusted by body temperature and
ambient pressure. These spirometric tests were performed in
accordance with American Thoracic Society guidelines (33, 34).
In this study, approximate normal distributions were observed
for both FEV1 and FVC.
Dietary assessment
Since May of 1992, the average daily dietary intakes of food
and beverage items were assessed with a self-administered,
validated, semi-quantitative FFQ adapted from the questionnaire
used in the Nurses’ Health Study. Details on the reproducibility
and validity of this FFQ for estimating daily nutrient intakes
were published elsewhere (35, 36). A database for assessment of
intake of the different flavonoid subclasses was constructed as
previously described (22) and was based on the updated and
expanded USDA flavonoid content of foods and the proantho-
cyanidin databases (37, 38) together with other sources. Intakes
of individual compounds were calculated as the sum of the
consumption frequency of each food multiplied by the content
of the specific flavonoid for the specified portion size. We de-
rived intakes (mg/d) of the subclasses commonly consumed in
the US diet, specifically anthocyanins (cyanidin, delphinidin,
malvidin, pelargonidin, petunidin, peonidin), flavanones (erio-
dictyol, hesperetin, naringenin), flavan-3-ols (catechins, gallo-
catechins, epicatechin, epigallocatechin, epicatechin-3-gallate,
epigallocatechin-3-gallate), flavonols (quercetin, kaempferol,
myricetin, isohamnetin), flavones (luteolin, apigenin), and
polymers (including proanthocyanidins excluding monomers,
theaflavins, and thearubigins). Refer to the Supplemental Ma-
terial for additional details describing the FFQ and computation
of flavonoid subclasses.
Statistical analysis
All statistical analyses were carried out by using SAS version
9.3 (SAS Institute). Utilizing concurrent measures of lung
10Abbreviations used: FEV1, forced expiratory volume in 1 s; FFQ, food-
frequency questionnaire; FVC, forced vital capacity; Nrf2, Nuclear factor,
erythroid 2-like 2.
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function, flavonoid intake, and covariates, we used time-varying
linear mixed-effects regression models with random participant-
specific intercepts, which account for the correlation of repeated
measures (39), to model continuous FEV1 and FVC as a function
of major subclass of flavonoid intake. Each flavonoid subclass
was characterized in quartiles (lowest quartile as reference) and
was fit in a separate model and adjusted for age at first visit,
height (cm), total energy intake (kcal/d, in quartiles), and time
since first visit; we estimated the adjusted difference in annual
change in lung function over time associated with flavonoid
intake via an interaction between each flavonoid quartile (lowest
quartile as reference) and time since first visit in the model.
All of the models were further adjusted for nondietary and
dietary factors that were ascertained at each visit, including the
following: race (black or white as reference), smoking status
(current smoker, recent quitter, longtime quitter, or never smoker
as reference), cumulative pack-years smoked, physician di-
agnosis of chronic bronchitis or asthma or emphysema (no as
TABLE 1
Characteristics of participants at first visit by quartiles of total anthocyanin intake1
Anthocyanin intake [median (IQR)]
Characteristics
Quartile 1:
1.1 (0.5, 1.6) mg/d
Quartile 2:
3.6 (2.8, 4.4) mg/d
Quartile 3:
12.7 (8.0, 13.7) mg/d
Quartile 4:
21.1 (16.5, 27.4) mg/d
Participants, n 211 208 210 210
FEV1, mL 2747.4 6 668.6
2 2789.2 6 630.4 2838.1 6 628.1 2893.4 6 634.6
FVC, mL 3681.8 6 764.9 3760.3 6 735.5 3787.5 6 742.1 3850.8 6 754.7
Age, y 65.8 6 7.1 67.6 6 7.0 67.1 6 6.5 66.8 6 6.7
Height, cm 1730.7 6 68.9 1736.0 6 71.9 1737.2 6 64.3 1743.0 6 65.6
Smoking status, n (%)
Current smokers 20 (9.5) 14 (6.7) 7 (3.3) 6 (2.9)
Recent quitters (,10 y) 30 (14.2) 27 (13.0) 21 (10.0) 20 (9.5)
Longtime quitters ($10 y) 107 (50.7) 104 (50.0) 122 (58.1) 117 (55.7)
Never smokers 54 (25.6) 63 (30.3) 60 (28.6) 67 (31.9)
Cumulative pack-years 27.0 6 29.2 19.6 6 22.4 20.9 6 28.2 16.2 6 22.1
Race, n (%)
Black 1 (0.5) 6 (2.9) 5 (2.4) 1 (0.5)
White 210 (99.5) 202 (97.1) 205 (97.6) 209 (99.5)
Years of education 14.1 6 2.9 14.5 6 2.8 15.4 6 2.8 15.5 6 2.9
Percentage below poverty level in census tract 6.4 6 5.5 6.8 (5.9) 5.8 (5.1) 5.7 (4.7)
Physician-diagnosed asthma, n (%) 14 (6.6) 9 (4.3) 12 (5.7) 6 (2.9)
Physician-diagnosed chronic bronchitis, n (%) 14 (6.6) 12 (5.8) 16 (7.6) 10 (4.8)
Physician-diagnosed emphysema, n (%) 8 (3.8) 11 (5.3) 14 (6.7) 8 (3.8)
Use of asthma medications, n (%) 6 (2.8) 13 (6.3) 7 (3.3) 5 (2.4)
Use of statins, n (%) 29 (13.7) 29 (13.9) 29 (13.8) 29 (13.8)
Metabolic equivalent tasks/wk 11.4 6 13.4 18.5 6 24.7 20.2 6 25.4 22.2 6 27.6
Total energy intake, kcal/d 1678.3 6 568.7 2005.7 6 592.0 2060.3 6 567.9 2249.1 6 651.4
Total fruit intake, servings/d 1.7 6 1.2 2.6 6 1.5 2.7 6 1.5 3.6 6 2.1
Total vegetable intake, servings/d 2.4 6 1.6 3.2 6 1.7 3.5 6 1.9 4.3 6 2.3
Total dietary fiber intake,3 mg/d 15.5 6 6.2 20.6 6 6.5 22.4 6 8.7 25.4 6 9.0
Hot and cold cereal intake, servings/d 0.4 6 0.4 0.5 6 0.4 0.5 6 0.4 0.6 6 0.6
Vitamin C intake (without supplements), mg/d 121.6 6 70.0 169.1 6 88.6 169.4 6 70.8 209.9 6 115.1
Caffeine intake, mg/d 249.3 6 191.2 250.7 6 194.5 231.8 6 186.5 207.1 6 178.6
n–3 Intake,4 g/d 0.3 6 0.3 0.3 6 0.3 0.3 6 0.2 0.4 6 0.4
Dark fish intake, servings/d 0.0 6 0.1 0.1 6 0.1 0.1 6 0.1 0.1 6 0.1
Other fish intake, servings/d 0.1 6 0.1 0.1 6 0.2 0.1 6 0.1 0.1 6 0.1
Cold cuts, servings/d 0.2 6 0.4 0.2 6 0.2 0.2 6 0.4 0.1 6 0.2
Flavanones, mg/d 44.8 6 45.0 59.3 6 46.3 56.8 6 39.9 65.2 6 43.9
Flavan-3-ols, mg/d 45.2 6 59.1 52.7 6 60.1 51.7 6 58.5 60.3 6 61.7
Flavonols, mg/d 14.8 6 10.0 18.6 6 10.9 19.4 6 10.9 24.7 6 12.3
Flavones, mg/d 1.8 6 1.5 2.5 6 1.5 2.6 6 1.3 3.4 6 1.8
Polymers, mg/d 154.3 6 193.9 207.0 6 204.8 213.5 6 207.0 267.0 6 207.3
Hypertension, n (%) 125 (59.2) 125 (60.1) 120 (57.1) 117 (55.7)
Coronary heart disease, n (%) 41 (19.4) 39 (18.8) 37 (17.6) 39 (18.6)
Diabetes mellitus, n (%) 34 (16.1) 30 (14.4) 26 (12.4) 23 (11.0)
Obesity (BMI $30 kg/m2), n (%) 59 (28.0) 55 (26.4) 49 (23.3) 49 (23.3)
1n = 839. Quartile distribution of anthocyanin intake was derived from intake estimated at first visit; the median (IQR) for year of first visit was 1994
(1993, 1996). FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
2Unadjusted mean 6 SD (all such values).
3Excluding 160 participants with a first visit in 1992 when estimation of total fiber intake was not available; numbers of participants in quartiles 1, 2, 3,
and 4 are 173, 164, 167, and 175, respectively.
4Includes EPA and DHA, no a-linolenic acid.
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reference), use of medication for asthma (no as reference), use of
statins (no as reference), years of education (,12, 12, 13–15,
.15 y as reference), percentage of census tract below poverty
level, total fruit intake (servings/d, in quartiles), total vegetable
intake (servings/d, in quartiles), and physical activity (metabolic
equivalent tasks/wk, in quartiles). We evaluated effect modification
by smoking status (ever or never), physician-diagnosed obstructive
lung disease (asthma, chronic bronchitis, or emphysema), and
obesity [BMI (in kg/m2)$30 or,30]. Three-way interaction terms
between flavonoid subclass intake, time since first visit, and the
modifying variables were tested separately to evaluate whether
the potential effect modifiers underlie susceptibility to the exposure
response.
In addition, we adjusted for the intake of hot or cold cereal
(servings/d), dark fish (servings/wk), processed meats (servings/d),
caffeine (mg/d), vitamin C (without supplements, mg/d), omega-3
fatty acids (g/d), total dietary fiber intake (g/d), and for the
presence of comorbid conditions including hypertension, cor-
onary heart disease, and diabetes mellitus. We also conducted
food-based analyses of the main sources of each flavonoid
subclass for all FFQs collected between 1992 and 2004 (n =
3366). Because healthier men may be more likely to participate
in a subsequent follow-up visits, we also applied stabilized
inverse probability weights to correct for this potential survival
bias (40) in all models. Refer to the Supplemental Material for
additional description of the computation of stabilized inverse
probability weights.
RESULTS
Characteristics of the participants by yearly average antho-
cyanin intake measured at first visit are presented in Table 1. The
median age of all of the participants at the first visit was 66.8 y,
with an age range of 49–92 y. Participants with higher antho-
cyanin intakes smoked less, were more physically active, and
consumed more fruit and vegetables. The mean follow-up time
for all participants was 7.4 y, and the maximum follow-up time
was 16 y. The distributions of FEV1 and FVC levels among
all participants at each visit are summarized in Supplemental
Table 1.
After multivariate adjustment for a range of lifestyle and di-
etary factors, higher total anthocyanin intake significantly (P ,
0.05) attenuated the rates of age-related annual decline in FEV1
and FVC (Figures 1 and 2, respectively). Compared with par-
ticipants in the first quartile, participants in the fourth quartile of
anthocyanin intake had a slower rate of FEV1 decline by 23.6
(95% CI, 16.6, 30.7) mL/y (Figure 1, Table 2). The linear
trend for adjusted difference in annual change in FEV1 across
quartiles of increasing anthocyanin intake was also significant
(P-trend , 0.0001). A similar pattern of association was also
observed for FVC as shown in Figure 2. Compared with par-
ticipants in the first quartile, participants in the fourth quartile of
anthocyanin intake had a slower rate of decline in FVC by 37.3
(95% CI: 27.8, 46.8) mL/y (P-trend , 0.0001) (Figure 2, Table
3). There was little difference in the observed associations for
anthocyanin intake between the minimal and fully adjusted
FIGURE 1 Adjusted mean (95% CI) annual decline in FEV1 by quartile
of total anthocyanin intake. The annual FEV1 decline for each quartile of
anthocyanin intake was estimated in a linear mixed regression model of
FEV1 with a random intercept for study participant and adjusting for the
following covariates: time since first visit, age at first visit, height, race,
presence of obstructive lung diseases, asthma medication use, statin medi-
cation use, education, percentage of census tract below poverty level, smok-
ing status, pack-years of smoking, physical activity, total energy intake, total
fruit intake, total vegetable intake, and 2-way interaction terms between time
since first visit and each quartile of anthocyanin intake; the variable coeffi-
cient for time since first visit reflects the adjusted mean annual FEV1 decline
for quartile of anthocyanin intake that is assigned the reference category.
1The P value for test of linear trend across quartile categories of anthocyanin
intake was based on a linear mixed regression model in which the value of
median intake was assigned to each category of anthocyanin intake; this
quartile median variable was used as a continuous measure in the regression
model. 2P values for quartiles 2, 3, and 4 are for the F test comparison with
quartile 1. 3Median values are presented for each quartile category of antho-
cyanin intake. FEV1, forced expiratory volume in 1 s.
FIGURE 2 Adjusted mean (95% CI) annual decline in FVC by quartile
of total anthocyanin intake. The annual FVC decline for each quartile of
anthocyanin intake was estimated in a linear mixed regression model of FVC
with a random intercept for study participant and adjusting for the following
covariates: time since first visit, age at first visit, height, race, presence of
obstructive lung diseases, asthma medication use, statin medication use,
education, percentage of census tract below poverty level, smoking status,
pack-years of smoking, physical activity, total energy intake, total fruit in-
take, total vegetable intake, and 2-way interaction terms between time since
first visit and each quartile of anthocyanin intake; the variable coefficient for
time since first visit reflects the adjusted mean annual FVC decline for
quartile of anthocyanin intake that is assigned the reference category. 1The
P value for test of linear trend across quartile categories of anthocyanin
intake was based on a linear mixed regression model in which the value
of median intake was assigned to each category of anthocyanin intake; this
quartile median variable was used as a continuous measure in the regression
model. 2P values for quartiles 2, 3, and 4 are for the F test comparison with
quartile 1. 3Median values are presented for each quartile category of antho-
cyanin intake. FVC, forced vital capacity.
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models (Tables 2 and 3, respectively). Furthermore, the observed
associations between anthocyanin intake and annual change in
FEV1 and FVC were robust after the application of stabilized
inverse probability weights.
To a lesser extent, an attenuation of lung function decline was
also observed for intake of flavan-3-ols and polymers in the
highest quartile. After application of stabilized inverse proba-
bility weights, participants in the fourth quartile of flavan-3-ol
intake had a significantly slower rate of decline in FEV1 and FVC
by 7.1 (95% CI: 0.4, 13.9) and 9.5 (95% CI: 0.4, 18.5) mL/y,
respectively (P-trend = 0.02) compared with participants in the
lowest quartile (Tables 2 and 3, respectively). A positive association
of similar magnitude was observed for polymer intake in the fourth
quartile and annual change in FVC (P-trend = 0.03) (Table 3).
The results for the other flavonoid subclasses are presented in
the Supplemental Tables 2 and 3. No significant associations
were observed for flavonol and flavone subclasses. Significant
negative associations were observed between the second and
fourth quartiles of flavonone intake and annual change in FVC,
indicating faster decline in FVC in association with flavonone
intake (Supplemental Table 3); in contrast, a positive association
of similar magnitude was observed for flavonone intake in the
second quartile and a linear trend was not observed. However,
the observed changes in FVC for the second and fourth quartiles
of flavonone intake were reduced moderately after the applica-
tion of stabilized inverse probability weights and were non-
significant.
After stratification by smoking status, slower rates of annual
decline in FEV1 and FVC in association with total anthocyanin
intake were observed in both current/former smokers and in
never smokers (Supplemental Table 4). Although the slowest
rates of decline in association with anthocyanin intake were
TABLE 2






Adjusted difference in mean annual change in FEV1 relative
to quartile 1
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-trend2
Anthocyanins
Median intake, mg/d 1.3 4.4 13.6 25.3 —
Person-visits, n 657 654 656 656 —
Minimally adjusted model3 251.4 6 2.74 7.6 (0.2, 15.2)5 12.3 (5.2, 19.5) 22.8 (15.8, 29.78) ,0.0001
Fully adjusted model6 251.7 6 2.8 7.8 (0.3, 15.2) 13.0 (5.8, 20.2) 23.6 (16.6, 30.7) ,0.0001
IPW model7 252.0 6 2.8 6.8 (20.6, 13.7) 13.7 (6.6, 20.9) 22.9 (15.9, 29.9) ,0.0001
Flavan-3-ols
Median intake, mg/d 9.7 21.4 45.7 99.3 —
Person-visits, n 656 655 656 656 —
Minimally adjusted model3 241.1 6 2.5 2.1 (24.9, 9.0) 2.0 (24.9, 9.0) 6.2 (20.5, 12.9) 0.07
Fully adjusted model6 241.2 6 2.6 1.9 (25.1, 8.9) 2.7 (24.3, 9.6) 6.6 (20.1, 13.3) 0.05
IPW model7 242.2 6 2.6 0.9 (26.2, 7.9) 4.7 (22.2, 11.6) 7.1 (0.4, 13.9) 0.02
Polymers
Median intake, mg/d 46.6 109.3 201.6 440.6 —
Person-visits, n 656 655 656 656 —
Minimally adjusted model3 241.2 6 2.6 0.3 (26.8, 7.4) 4.0 (23.1, 11.1) 5.8 (21.1, 12.6) 0.08
Fully adjusted model6 241.3 6 2.7 0.6 (26.6, 7.7) 4.4 (22.8, 11.5) 6.1 (20.8, 13.0) 0.07
IPW model7 242.3 6 2.7 0.8 (26.4, 8.0) 5.4 (21.7, 12.5) 6.7 (20.2, 13.6) 0.05
1FEV1, forced expiratory volume in 1 s; IPW, inverse probability weight.
2P values for the test of linear trend across quartile categories of flavonoid subclass intake were based on a linear mixed
regression model with the value of median intake assigned to each quartile category of flavonoid subclass intake; this
quartile median variable was used as a continuous measure in the regression model.
3As estimated in linear mixed-effects regression model of FEV1 with a random intercept for study participant and
adjusting for the following covariates: flavonoid intake (mg/d, in quartiles), time since first visit (y), age at first visit (y),
height (cm), and total energy intake (kcal/d, in quartiles); b is the variable coefficient for the interaction between time since
first visit and category of flavonoid subclass intake where quartile 1 is the reference category.
4Mean 6 SEM (all such values).
5b; 95% CI in parentheses (all such values).
6The fully adjusted model includes additional adjustment for race (black or white as reference), smoking status (current
smoker, recent quitter, longtime quitter, or never smoker as reference), cumulative pack-years smoked, physician diagnosis
of chronic bronchitis or asthma or emphysema (no as reference), asthma medication use (no as reference), statin medication
use (no as reference), years of education (,12, 12, 13–15, .15 y as reference), percentage of census tract below poverty
level, total fruit intake (servings/d, in quartiles), total vegetable intake (servings/d, in quartiles), and physical activity
(metabolic equivalent tasks/wk, in quartiles).
7The IPW model is the fully adjusted model after application of stabilized inverse weights for censoring by loss to
follow-up.
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found in never smokers, a 3-way interaction between smoking
status, anthocyanin intake, and time since first visit on lung func-
tion was not significant. Similarly, no interactions were observed
between anthocyanin intake and the presence of obstructive lung
diseases and obesity (data not shown). The adjusted differences
in annual lung function decline for anthocyanin intake remained
robust after additional individual adjustment for intakes of
total dietary fiber, hot or cold breakfast cereal, vitamin C,
caffeine, n–3 fatty acids, fish, and processed meats and for the
presence of comorbid conditions including hypertension,
coronary heart disease, and diabetes mellitus (Supplemental
Tables 5 and 6).
The results of food-based analyses utilizing all FFQs collected
between 1992 and 2004 indicate that intakes of blueberries
(49.9%), red wine (17.6%), and strawberries (15.5%) contributed
most to overall anthocyanin intake. To confirm our findings for
total anthocyanin intake and to relate the effects on lung function
decline to public health and dietary guidelines, we examined
associations between weekly intakes of blueberries, red wine, and
strawberries and annual change in lung function. Blueberry in-
takewas associated with the slowest rate of annual decline in lung
function; compared with no or very low intake, consuming $2
servings of blueberries/wk was associated with a slower rate of
decline in FEV1 and FVC by 22.5 (95% CI: 10.5, 34.2) and 37.6
(95% CI: 21.8, 53.4) mL/y, respectively (P-trend , 0.0001)
(Table 4). To a lesser extent, similar findings were observed for
strawberry intake. No significant associations were observed for
red wine intake (data not shown).
DISCUSSION
Our findings suggest that habitual anthocyanin intake was
associated with slower age-related decline in FEV1 and FVC,
independent of established dietary and nondietary risk factors.
In addition, an attenuation of lung function decline associated
with anthocyanin intake was stronger in never smokers than in
TABLE 3





Adjusted difference in mean annual change
in FVC relative to quartile 1
Quartile 2 Quartile 3 Quartile 4 P-trend2
Anthocyanins
Median intake, mg/d 1.3 4.4 13.6 25.3
Person-visits, n 657 654 656 656
Minimally adjusted model3 269.5 6 3.74 13.7 (3.7, 23.8)5 18.7 (9.0, 28.4) 36.5 (27.0, 45.9) ,0.0001
Fully adjusted model6 268.9 6 3.8 13.7 (3.6, 23.7) 19.2 (9.5, 28.9) 37.3 (27.8, 46.8) ,0.0001
IPW model7 268.4 6 3.7 11.2 (1.2, 21.2) 19.2 (9.6, 28.8) 35.6 (26.2, 45.0) ,0.0001
Flavan-3-ols
Median intake, mg/d 9.7 21.4 45.7 99.3
Person-visits, n 656 655 656 656
Minimally adjusted model3 251.3 6 3.3 3.2 (26.3, 12.7) 22.4 (211.8, 7.1) 8.4 (20.8, 17.5) 0.09
Fully adjusted model6 250.3 6 3.5 2.4 (27.0, 11.9) 22.0 (211.4, 7.4) 8.6 (20.5, 17.8) 0.06
IPW model7 251.4 6 3.5 0.6 (28.9, 10.0) 1.2 (28.2, 10.5) 9.5 (0.4, 18.5) 0.02
Polymers
Median intake, mg/d 46.6 109.3 201.6 440.6
Person-visits, n 656 655 656 656
Minimally adjusted model3 252.4 6 3.5 0.7 (28.9, 10.4) 3.8 (25.8, 13.5) 8.5 (20.8, 17.8) 0.05
Fully adjusted model6 251.3 6 3.7 0.5 (29.2, 10.1) 3.9 (25.7, 13.6) 8.4 (20.9, 17.7) 0.05
IPW model7 252.8 6 3.7 0.7 (29.1, 10.4) 6.3 (23.4, 15.9) 9.5 (0.2, 18.8) 0.03
1FVC, forced vital capacity; IPW, inverse probability weight.
2P values for the test of linear trend across quartile categories of flavonoid subclass intake were based on a linear
mixed regression model with the value of median intake assigned to each quartile category flavonoid subclass intake; this
quartile median variable was used as a continuous measure in the regression model.
3As estimated in linear mixed-effects regression model of FVC with a random intercept for study participant and
adjusting for the following covariates: flavonoid intake (mg/d, in quartiles), time since first visit (y), age at first visit (y),
height (cm), and total energy intake (kcal/d, in quartiles); b is the variable coefficient for the interaction between time since
first visit and category of flavonoid subclass intake where quartile 1 is the reference category.
4Mean 6 SEM (all such values).
5b; 95% CI in parentheses (all such values).
6The fully adjusted model includes additional adjustment for race (black, white as reference), smoking status (current
smoker, recent quitter, longtime quitter, or never smoker as reference), cumulative pack-years smoked, physician diagnosis
of chronic bronchitis or asthma or emphysema (no as reference), asthma medication use (no as reference), statin medication
use (no as reference), years of education (,12, 12, 13–15, .15 y as reference), percentage of census tract below poverty
level, total fruit intake (servings/d, in quartiles), total vegetable intake (servings/d, in quartiles), and physical activity
(metabolic equivalent tasks/wk, in quartiles).
7The IPW model is the fully adjusted model after application of stabilized inverse weights for censoring by loss to
follow-up.
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ever smokers. To a lesser extent, an attenuation of lung function
decline was also observed for intakes of flavan-3-ols and poly-
mers in the highest quartile. The beneficial changes in lung
function over time associated with anthocyanin intake comple-
ment findings from recent studies that suggest protective effects
of these compounds on a number of chronic diseases including
cardiovascular disease and associated risk factors (22–24, 41).
Anthocyanins are present in red/blue fruits and may, in part,
explain the previously reported population-based evidence that
showed that fruit consumption was positively related to lung
function and protective against the incidence of chronic non-
specific lung diseases (7, 42, 43). In food-based analyses of the
main anthocyanin sources, an attenuation of lung function decline
was also observed for frequent intakes of blueberries and
strawberries. The beneficial changes in lung function associated
with frequent consumption of berries may possibly exceed the
decline in lung function attributable to smoking, assuming that
moderate- to-heavy smoking men have, on average, a 15-mL/y
larger decline in FEV1 than do nonsmokers (44). The beneficial
change in FEV1 associated with the highest quartile of antho-
cyanin intake is within the range of a previously reported as-
sociation between vitamin C intake and reduction in decline in
FEV1 (50.8 mL/y; 95% CI: 3.8, 97.9 mL/y) from a general
population–based study in the United Kingdom (8).
The present study provides novel evidence that suggests that
berries may contain specific constituents that may attenuate lung
function decline. The addition of total dietary fiber, vitamin C,
and other dietary constituents, including total fruit and total
vegetable intake, to our multivariate model did not substantially
influence the observed associations between anthocyanin intake
and longitudinal change in lung function. These findings suggest
that the benefits of anthocyanins are specific and not simply
reflective of those who eat a high-plant-based diet.
A growing body of evidence from experimental studies sup-
ports a role for anthocyanins and their degradation products/
microbial metabolites on mechanisms involved in lung function.
The microbiome is likely to play a key role in the bioactivity of
anthocyanins because degradation is swift after intake and the
microbially derived metabolites are present in the circulation
longer and at higher concentrations than the parent anthocyanins
(45–48). Recent findings from in vitro studies suggest that nu-
tritionally relevant amounts of these downstream metabolites
exert a greater anti-inflammatory effect than the parent mole-
cules (49, 50), although the impact on airway inflammation is
unknown. Previous studies also showed that anthocyanins, in-
cluding anthocyanin-rich bilberry extract, can inhibit the acti-
vation of nuclear transcription factor kB (51–53) and attenuate
oxidative stress through activations of the Nuclear factor, ery-
throid 2-like 2 (Nrf2) signaling pathway (54). In a recent cross-
sectional analysis in 2375 Framingham Heart Study Offspring
Cohort participants, habitual intakes of both total anthocyanins
and strawberries were inversely associated with a combined
inflammatory score, which integrated a range of inflammatory
and oxidative stress biomarkers (24). In the limited experimental
human studies conducted to date, berry intake was also associ-
ated with improved markers of oxidative stress including cell
antioxidant defense against DNA damage (28, 29, 55, 56).
Only 2 previous observational studies (20, 21) examined as-
sociations between flavonoid intake and lung function. These
studies used earlier flavonoid databases that covered only a few
subclasses and did not include anthocyanins or flavanones. When
combining the intakes of flavan-3-ol, flavonol, and flavone
subclasses, a 44-mL higher difference in FEV1 level was ob-
served when comparing extreme intake quintiles (117 compared
with 15 mg/d) in a large cross-sectional analysis in 13,651 adults
in the Netherlands (20). Similarly, investigators in Chile ob-
served 100- and 70-mL differences in FVC level when com-
paring highest to lowest quintiles of flavonol and flavan-3-ol
intakes, respectively, in a cross-sectional analysis in 1232 young
adults (21). Although we hypothesized that higher intakes of
TABLE 4
Adjusted differences in mean annual change in lung function (mL/y) for blueberry and strawberry intakes1
Mean annual change Adjusted difference in mean annual change
No intake or ,1 serving/mo ,1 serving/wk 1 serving/wk $2 servings/wk P-trend2
Blueberries
Person-visits, n 1596 723 196 108
FEV1 241.5 6 1.7
3 2.9 (22.7, 8.4)4 17.0 (7.7, 26.3) 22.5 (10.8, 34.2) ,0.0001
FVC 253.1 6 2.3 7.0 (20.5, 14.5) 18.5 (6.0, 31.1) 37.9 (22.1, 53.7) ,0.0001
Strawberries
Person-visits, n 1188 963 304 168
FEV1 242.8 6 2.0 4.8 (20.6, 10.3) 14.5 (6.6, 22.5) 13.1 (3.8, 22.4) ,0.0001
FVC 251.4 6 2.7 7.7 (0.3, 15.1) 16.1 (5.3, 26.1) 19.7 (7.0, 32.3) ,0.0001
1As estimated in linear mixed regression models of FEV1 (and FVC) with a random intercept for study participant and
adjusting for the following covariates: time since first visit, age at first visit, height, race, smoking status, cumulative pack-
years smoked, physician diagnosis of chronic bronchitis or asthma or emphysema, asthma medication use, statin use, years
of education, percentage of census tract below poverty level, total energy intake, total fruit intake, total vegetable intake,
and physical activity. b is the variable coefficient for the interaction between time since first visit and category of blueberry
and strawberry intake where no intake or ,1 serving/mo is the reference category. FEV1, forced expiratory volume in 1 s;
FVC, forced vital capacity.
2P values for the test of linear trend across categories of blueberry (and strawberry) intake were based on a linear
mixed regression model where the ordinal variable for blueberry (and strawberry) intake was used as a continuous measure.
3Mean 6 SEM (all such values).
4b; 95% CI in parentheses (all such values).
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flavones, flavonols, flavan-3-ols, and their polymeric forms would
also attenuate lung function decline over time, no associations were
observed for flavone and flavonol intake in the present study.
However, a slower decline in FEV1 and FVC over time was also
observed with a high intake of flavan-3-ols. A similar finding was
also observed for a high intake of polymers and FVC decline.
The strengths of this study include the longitudinal design with
multiple repeat measures of dietary flavonoid intake and lung
function to evaluate longitudinal change, a large sample size with
long-term follow-up, adjustment for multiple confounders, and
methods to address selection bias. Our databases also allowed us
to comprehensively assess the range of flavonoids present in the
habitual diet. However, there are a number of limitations to
consider. Our findings relate to predominantly elderly white men;
thus, the generalizability to women and younger and other racial-
ethnic population groups requires further study. Although we ad-
justed for possible confounders that are known to be associated with
lung function, there remains the possibility of residual confounding
with respect to these factors or unmeasured confounding from
additional unmeasured factors. However, given our detailed and
updated adjustment for potential confounders, it is unlikely that
these would account fully for the associations we observed.
Average daily flavonoid subclass intakes were calculated from
a database developed by using recent USDA databases with ad-
ditional input from European Union sources (EuroFIR eBASIS;
http://www.eurofir.org), allowing us to robustly assess intakes
using the best available databases at the time. Flavonoid content
also varies depending on a number of factors, including growing
conditions, processing, and storage; however, despite these
variations, these data allowed us to rank participants and compare
low and high intakes in large population groups. Although our
FFQ has not been specifically validated for intakes of flavonoid
subclasses, correlations between the main dietary sources of
flavonoids (fruit, tea, vegetables, and wine) have been determined
for our FFQ (57, 58) and flavonoid biomarkers are correlated with
intakes of fruit and vegetables (59). Current research is moving
closer to identifying biomarkers of anthocyanin intake (46), but it
is possible that our findings for anthocyanins might be due to
other constituents found in the foods that contribute most to this
subclass. However, even additional adjustment of other poten-
tially beneficial constituents of fruit, including vitamin C and
fiber, did not substantially attenuate the relation between an-
thocyanins and lung function, suggesting that anthocyanins may
be another important dietary constituent. In an observational
cohort study such as the VA Normative Aging Study, it is im-
possible to disentangle the relative influence of all of the con-
stituents of plant-based foods.
In summary, we observed that a higher dietary intake of an-
thocyanins was associated with an attenuation of lung function
decline in this longitudinal sample of predominantly elderly
white men. The present findings suggest a potential role for
anthocyanins in berry fruit in slowing age-related decline in lung
function. Further prospective studies are needed to confirm these
novel associations.
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